{
    "root": "34f4870b-c857-c0d9-e063-6294a90a011a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Hydroxyzine Hydrochloride",
    "value": "20250512",
    "ingredients": [
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM CITRATE",
            "code": "1Q73Q2JULR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53258"
        },
        {
            "name": "HYDROXYZINE DIHYDROCHLORIDE",
            "code": "76755771U3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5818"
        }
    ],
    "indications": {
        "text": "symptomatic relief anxiety tension associated psychoneurosis adjunct organic disease states anxiety manifested . useful management pruritus due allergic conditions chronic urticaria atopic contact dermatoses , histamine-mediated pruritus . sedative used premedication following general anesthesia , hydroxyzine may potentiate meperidine ( demerol \u00ae ) barbiturates , pre-anesthetic adjunctive therapy modified individual basis . atropine belladonna alkaloids affected . hydroxyzine known interfere action digitalis way may used concurrently agent . effectiveness hydroxyzine antianxiety agent long term , 4 months , assessed systematic . physician reassess periodically usefulness individual patient .",
        "doid_entities": [
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "psychoneurosis (DOID:4964)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4964"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "chronic urticaria (DOID:0080747)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080747"
            },
            {
                "text": "urticaria (DOID:1555)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1555"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic urticaria atopic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_182734"
            }
        ]
    },
    "contraindications": {
        "text": "symptomatic relief anxiety tension associated psychoneurosis adjunct organic disease states anxiety manifested : adults , 50 100 mg four times daily . : children 6 years , 50 mg daily divided doses : children 6 years : 50 100 mg daily divided doses . management pruritus due allergic conditions chronic urticaria atopic contact dermatoses , histamine-mediated pruritus : adults , 25 mg three times four times daily . ; children 6 years , 50 mg daily divided doses children 6 years , 50 100 mg daily divided doses . sedative used premedication following general anesthesia : 50 100 mg adults , 0.6 mg/kg children . treatment initiated intramuscular route , subsequent doses may administered orally . medications , adjusted according patient \u2019 response therapy .",
        "doid_entities": [
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "psychoneurosis (DOID:4964)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4964"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "chronic urticaria (DOID:0080747)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080747"
            },
            {
                "text": "urticaria (DOID:1555)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1555"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic urticaria atopic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_182734"
            }
        ]
    },
    "warningsAndPrecautions": "hydroxyzine hydrochloride syrup ( hydroxyzine hydrochloride oral solution , usp ) 10 mg per 5 ml ( teaspoonful ) slightly yellow peppermint flavored liquid , supplied 473 ml ( 16 fl . oz . ) amber plastic bottles . ndc 17856-0507-01 hydroxyzine hcl 10mg/5ml - 5 ml cup 72 ct ud store controlled room temperature 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature ] . dispense tight , light-resistant container child-resistant closure defined usp . distributed : atlantic biologicals corp. miami , fl 33179",
    "adverseReactions": "oral hydroxyzine hydrochloride contraindicated patients known hypersensitivity hydroxyzine hydrochloride products , patients known hypersensitivity cetirizine hydrochloride levocetirizine hydrochloride . hydroxyzine contraindicated patients prolonged qt interval . hydroxyzine , administered pregnant mouse , rat rabbit , induced fetal abnormalities rat mouse doses substantially human therapeutic range . data human beings inadequate establish safety early pregnancy . data available , hydroxyzine contraindicated early pregnancy . hydroxyzine contraindicated patients shown previous hypersensitivity component medication .",
    "indications_original": "For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.\n                  Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.\n                  As a sedative when used in premedication and following general anesthesia,\n \n  Hydroxyzine may potentiate meperidine(Demerol\n \n  \u00ae) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis.\n\n \n                  Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.\n                  The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.",
    "contraindications_original": "For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50 to 100 mg four times daily.: children under 6 years, 50 mg daily in divided doses: children over 6 years: 50 to 100 mg daily in divided doses.\n                  For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg three times to four times daily.; children under 6 years, 50 mg daily in divided doses and children over 6 years, 50 to 100 mg daily in divided doses.\n                  As a sedative when used as a premedication and following general anesthesia: 50 to 100 mg in adults, and 0.6 mg/kg in children.\n                  When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.\n                  As with all medications, the dosage should be adjusted according to the patient\u2019s response to therapy.",
    "warningsAndPrecautions_original": "Hydroxyzine Hydrochloride Syrup (Hydroxyzine Hydrochloride Oral Solution, USP) 10 mg per 5 mL (teaspoonful) is a slightly yellow peppermint flavored liquid, supplied in 473 mL (16 fl. oz.) amber plastic bottles.\n                  NDC 17856-0507-01\u00a0HYDROXYZINE HCL 10MG/5ML - 5 ML CUP 72 ct UD\n                  Store at controlled room temperature 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). [See USP controlled room temperature].\n                  Dispense in a tight, light-resistant container with child-resistant closure as defined in the USP.\n                  \n                  \n                  \n                     Distributed by:\n                  \n                  \n                     ATLANTIC BIOLOGICALS CORP.\n                  \n                  \n                     MIAMI, FL 33179",
    "adverseReactions_original": "Oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride.\n                  Hydroxyzine is contraindicated in patients with a prolonged QT interval.\n                  Hydroxyzine, when administered to the pregnant mouse, rat and rabbit, induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.\n                  Hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity\u00a0to any component of this medication.",
    "drug": [
        {
            "name": "Hydroxyzine Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5819"
        }
    ]
}